AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-98277687/nicox-requests-enquiry-following.html" title="Facts and information about NicOx requests enquiry following share collapse.">NicOx requests enquiry following share collapse.</a>

Close Set up an RSS feed that alerts you when new articles from Pharma Marketletter are available.

Frequently asked questions about RSS feeds

NicOx requests enquiry following share collapse.

Pharma Marketletter

| March 03, 2003 | COPYRIGHT 2009 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

French start-up company NicOx has requested an investigation by the nation's securities commission into transactions of its stock. The company is concerned about the weeks leading up to a press statement detailing the failure of a molecule, being developed alongside Anglo-Swedish drug major AstraZeneca, to meet its main criteria in Phase II trials (Marketletter February 24).

The request came after AstraZeneca and NicOx jointly disclosed that the naproxen-based analgesic AZD…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


NicOx Strengthens Management Team With Two Appointments.: Press release article from: PR Newswire October 15, 2001 700+ words
...Formulation. Both positions will report to Dr. Giancarlo Santus, Vice-President, Product Development of NicOx. Michele Garufi, Chief Executive Officer and Chairman of the Board of NicOx, said: "We are delighted to welcome Marco and...


NicOx, Merck enter agreement around Nitric Oxide compounds.: Newspaper article from: BioWorld International Etheridge, James August 27, 2003 700+ words
...drug compounds on a worldwide basis. Other terms and conditions of the agreement were not disclosed. The CEO of NicOx, Michele Garufi, welcomed the deal, describing it as "a strong endorsement of our leading position in nitric oxide-donating...


Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver...: Newspaper article from: Biotech Week March 11, 2009 700+ words
...its lead investigational drug for the treatment of the signs and symptoms of osteoarthritis (OA) (see also NicOx). Michele Garufi, Chief Executive Officer of NicOx, commented: "We believe NicOx has entered 2009 in its strongest strategic...


NicOx Appoints Pascal Pfister MD as Chief Scientific Officer and Strengthens...: Press release article from: PR Newswire July 2, 2007 700+ words
...Officer (CSO). In this role Dr. Pfister will report to Michele Garufi, Chairman and CEO, and will have overall responsibility...NicOx' R&D in the cardiometabolic disease area. Michele Garufi, Chairman and CEO of NicOx, declared: "Dr. Pfister...


NicOx Announces the Appointment of Dr. Ali Raza as Head of R&D.: Press release article from: Business Wire June 14, 2005 700+ words
...Development, reporting to the Chief Executive Officer, Michele Garufi. Dr. Raza will be responsible for the Research, Drug...AstraZeneca, Dr. Raza worked for Sanofi Pharmaceuticals. Michele Garufi, Chairman and CEO of NicOx, commented: "Dr. Raza...


NicOx Strengthens Development Team: Staffan Stromberg Appointed VP Drug...: Press release article from: Business Wire June 1, 2005 700+ words
...Development, reporting to the Chief Executive Officer, Michele Garufi. Mr. Stromberg will be responsible for non-clinical...strategic portfolio management at all stages of development. Michele Garufi, Chairman and CEO of NicOx, commented: "These key appointments...


NicOx antihypertensive taken into Phase I trial by Merck.: Newspaper article from: BioWorld International Etheridge, James May 14, 2008 700+ words
...that the first of these has started patient dosing," said Michele Garufi, chairman and CEO of NicOx. "We look forward to continued...Pfizer to unlock this value," said NicOx Chairman and CEO Michele Garufi. "Moreover, the promising results from our joint research...


Dr. Goran Ando Joins NicOx Board of Directors.: Press release article from: Business Wire December 21, 2004 700+ words
...technology platform and promising development candidates." Michele Garufi, Chairman and CEO of NicOx, commented: "Dr. Ando...replaces that of Dr. Bjorn Odlander, CEO of HealthCap. Michele Garufi stated: "We are very grateful to Bjorn Odlander for his...


NicOx "clarifies" data position on AZD3582.: Newspaper article from: Pharma Marketletter March 17, 2003 700+ words
...while noting that its drug was equivalent to naproxen in terms of relieving the pain associated with osteoarthritis. Michele Garufi, NicOx' chief executive, said he believes that, based on this preliminary review, "this Phase II clinical trial clearly...


Clinical study to evaluate HCT 3012 effects on blood pressure initiated.: Newspaper article from: Life Science Weekly October 5, 2004 700+ words
...problem, it would be a clinically important improvement in the pharmacology of this class of widely-prescribed drugs." Michele Garufi, chairman and CEO of NicOx, added, "A broad phase II program, in more than 2700 patients, has already demonstrated...

For more facts and information, see all results

Source: HighBeam Research, NicOx requests enquiry following share collapse.

The AccessMyLibrary advertising network includes: